LONDON – Endomag Ltd. has received endorsement from the U.K. health technology assessment body NICE, opening the way to broader adoption of its Magtrace non-radioactive cancer staging technology in the National Health Service, and providing backing for commercialization of the system in other markets.
Scientists at Cleveland-based Case Western Reserve University have used artificial intelligence (AI) to identify biomarkers contained in naturally occurring collagen that could predict whether breast cancer will return after treatment. Identified from standard tissue biopsy slides of early-stage breast cancer, collagen-based assays could also be less expensive than gene expression-based assays typically conducted at highly specialized labs in California.
PARIS – Screenpoint Medical BV has just closed $28 million in series C funding to scale its latest generation of the Transpara system, which uses fusion AI for 2D and 3D mammography.
Astrazeneca plc and Daiichi Sankyo Co. Ltd. are pushing forward with a challenge to Roche Holding AG with breast cancer drug Enhertu (trastuzumab deruxtecan) after it demonstrated superiority over the Swiss firm’s Kadcyla (trastuzumab emtansine) in a head-to-head trial.
Astrazeneca plc and Daiichi Sankyo Co. Ltd. are pushing forward with a challenge to Roche Holding AG with breast cancer drug Enhertu (trastuzumab deruxtecan) after it demonstrated superiority over the Swiss firm’s Kadcyla (trastuzumab emtansine) in a head-to-head trial.
Zentera Therapeutics Inc. completed a $75 million series B financing round to help further its candidates in China, as it paves the way for a listing in Hong Kong next year.
Around 100,000 medical professionals have registered to learn breast cancer related information through Zhongchao Inc.’s Breast Cancer Tiered Diagnosis and Treatment Improvement Platform in the first half of 2021. It marks one of the earliest efforts conducted for the Healthy China 2030 Guidelines, which aims to increase the overall five-year cancer survival rate by 15% by 2030.
PERTH, Australia – After raising A$10 million (US$7.36 million) in its initial public offering on the Australian Securities Exchange, BCAL Diagnostics Ltd. is racing to commercialize its noninvasive, blood-based in vitro diagnostic to detect breast cancer. The Breast Cancer Associated Lipids (BCAL) test is taken via a blood sample and analyzed for lipid biomarkers.
In a deal that could bring Arvinas Inc. a potential $2.4 billion, the company will collaborate with Pfizer Inc. to develop and commercialize an oral estrogen receptor protein degrader. In addition to a potential $400 million in approval milestones and a possible $1 billion in commercial milestones, Arvinas will be paid $650 million up front by Pfizer, which will also make an equity investment of $350 million in Arvinas while receiving about 3.5 million newly issued Arvinas common stock shares. With the deal, Pfizer will have a 7% equity share in Arvinas. The two plan to equally divide development and commercialization costs as well as any profits.
A study led by researchers at the Olivia Newton-John Cancer Research Institute, La Trobe University, The Walter and Eliza Hall Institute, and the University of Melbourne has used a novel optical color-coding barcoded cancer cell tracking strategy to investigate metastatic heterogeneity in breast cancer.
